Marzban-Rad Saeid, Bahmani Sahar, Kazemi Amenehsadat, Taheri Hamid Reza
Department of Surgery, Imam-Reza Hospital, Aja University of Tehran Medical Sciences, Tehran, Iran.
Zist Takhmir Pharmaceutical Company, Tehran University of Medical Sciences, Tehran, Iran.
Ann Med Surg (Lond). 2022 Jun;78:103909. doi: 10.1016/j.amsu.2022.103909. Epub 2022 Jun 7.
and Importance: Severe COVID19 patients under anticoagulant therapy are at the risk of developing hematoma.
We present case of 11 COVID19 who were presented with localized skin ecchymosis lesions in different areas of the body and retroperitoneal hematoma in the posterior wall of the abdomen and chest.
Cases of hematoma with severe COVID19 patients under anticoagulant therapy are reported in several case studies, particularly in geriatric population with the previous history of blood and/or cardiac disorders.
These patients should be carefully monitored for hematomas by skilled nurse and practitioner and timely treated and monitored.
及重要性：接受抗凝治疗的重症新冠病毒疾病（COVID-19）患者有发生血肿的风险。
我们报告了11例COVID-19患者的病例，这些患者在身体不同部位出现局部皮肤瘀斑病变，以及腹部和胸部后壁的腹膜后血肿。
在一些病例研究中报告了接受抗凝治疗的重症COVID-19患者发生血肿的病例，特别是在有血液和/或心脏疾病既往史的老年人群中。
这些患者应由熟练的护士和医生仔细监测是否有血肿，并及时进行治疗和监测。
